QuantaLife has developed an innovative digital PCR (Polymerase Chain Reaction) system that provides quantification of target molecules with unprecedented precision and sensitivity.
This next generation PCR technology builds on the well established method of amplifying DNA that is used in research laboratories around the world.
Digital PCR provides researchers with a new tool for the detection of rare mutations including distinguishing rare sequences in tumors, precise measurement of copy number variation, and absolute quantification of gene expression.
"We are impressed with QuantaLife's digital PCR technology and believe it will complement Bio-Rad's existing amplification business," said Norman Schwartz, Bio-Rad President and CEO.
Schwartz continued, "This elegant solution expands the current state of the art methods of quantitative PCR (qPCR), and we look forward to its adoption in life science research."